- Home
- SABR vs CVAC Comparison
SABR vs CVAC Comparison
Compare SABR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- CVAC
- Stock Information
- Founded
- SABR 2006
- CVAC 2000
- Country
- SABR United States
- CVAC Germany
- Employees
- SABR N/A
- CVAC N/A
- Industry
- SABR Computer Software: Programming Data Processing
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- CVAC Health Care
- Exchange
- SABR Nasdaq
- CVAC Nasdaq
- Market Cap
- SABR 1.2B
- CVAC 1.2B
- IPO Year
- SABR 2014
- CVAC 2020
- Fundamental
- Price
- SABR $3.27
- CVAC $5.46
- Analyst Decision
- SABR Hold
- CVAC Hold
- Analyst Count
- SABR 5
- CVAC 3
- Target Price
- SABR $4.12
- CVAC $6.83
- AVG Volume (30 Days)
- SABR 4.7M
- CVAC 900.0K
- Earning Date
- SABR 08-07-2025
- CVAC 08-14-2025
- Dividend Yield
- SABR N/A
- CVAC N/A
- EPS Growth
- SABR N/A
- CVAC N/A
- EPS
- SABR N/A
- CVAC 0.87
- Revenue
- SABR $3,023,296,000.00
- CVAC $566,039,775.00
- Revenue This Year
- SABR $2.99
- CVAC N/A
- Revenue Next Year
- SABR $3.59
- CVAC $24.04
- P/E Ratio
- SABR N/A
- CVAC $6.30
- Revenue Growth
- SABR 2.56
- CVAC 787.60
- 52 Week Low
- SABR $1.93
- CVAC $2.37
- 52 Week High
- SABR $4.63
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- SABR 60.55
- CVAC 61.70
- Support Level
- SABR $2.95
- CVAC $5.42
- Resistance Level
- SABR $3.21
- CVAC $5.49
- Average True Range (ATR)
- SABR 0.15
- CVAC 0.07
- MACD
- SABR -0.02
- CVAC -0.05
- Stochastic Oscillator
- SABR 56.14
- CVAC 66.67
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.